Transaction DateRecipientSharesTypePriceValue
20th November 2020Garo H Armen4,049Grant/award etc.$3.65$14,778.85
6th November 2020Garo H Armen3,869Grant/award etc.$3.82$14,779.58
23rd October 2020Garo H Armen3,751Grant/award etc.$3.94$14,778.94
9th October 2020Garo H Armen3,397Grant/award etc.$4.35$14,776.95
25th September 2020Garo H Armen3,676Grant/award etc.$4.02$14,777.52
11th September 2020Garo H Armen2,962Grant/award etc.$4.99$14,780.38
28th August 2020Garo H Armen3,452Grant/award etc.$4.28$14,774.56
14th August 2020Garo H Armen3,984Grant/award etc.$3.71$14,780.64
31st July 2020Garo H Armen4,861Grant/award etc.$3.04$14,777.44
17th July 2020Garo H Armen4,105Grant/award etc.$3.60$14,778.00
Agenus
Agenus logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Agenus, Inc. engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.


Ticker: AGEN
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1098972
Employees: 328
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $79 M (28%)
Other Assets, Current: $1 M (27%)
Assets, Current: $105 M (21%)
Property, Plant and Equipment, Net: $29 M (8%)
Other Assets, Noncurrent: $1 M (2%)
Assets: $186 M (19%)
Long-term Debt, Current Maturities: $2 M (137%)
Accounts Payable, Current: $21 M (52%)
Accrued Liabilities, Current: $27 M (0%)
Liabilities, Current: $142 M (16%)
Long-term Debt, Excluding Current Maturities: $19 M (40%)
Other Liabilities, Noncurrent: $6 M (53%)
Common Stock, Value, Issued: $2 M (24%)
Common Stock, Shares, Issued: $171 M (24%)
Retained Earnings (Accumulated Deficit): $1 B (-1%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $369 Th (-72%)
Stockholders' Equity (Parent): $219 M (-2%)
Liabilities and Equity: $186 M (19%)
Revenue: $27 M (0%)
Research and Development: $39 M (-48%)
General and Administrative Expenses: $14 M (-42%)
Operating Income/Loss: $33 M (-45%)
Other Income, net: $340 Th (-75%)